Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity

Journal of the American Statistical Association

Volumn 110, Issue 510, 2015, Pages 711-722

  Lee, Juhee ^a   Thall, Peter F ^b   Ji, Yuan ^c   Müller, Peter ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adaptive design; Bayesian design; Dynamic treatment regime; Latent probit model; Phase I II clinical trial; Q learning

Indexed keywords

EID: 84936744053     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.2014.926815     Document Type: Article

References (53)

1. J.H.Albert,, S.Chib, (1993), Bayesian Analysis of Binary and Polychotomous Response Data, Journal of the American Statistical Association, 88, 66–99.
2. D.Almirall,, T.Have,, S.A.Murphy, (2010), Structural Nested Mean Models for Assessing Time-Varying Effect Moderation, Biometrics, 66, 131–139.
3. J.R.Ashford,, R.R.Sowden, (1970), Multi-Variate Probit Analysis, Biometrics, 26, 535–546.
4. D.Azriel,, M.Mandel,, Y.Rinott, (2011), The Treatment Versus Experiment Dilemma in Dose-Finding Studies, Journal of the Statistical Planning and Inference, 141, 2759–2768.
5. J.Bartroff,, T.L.Lai, (2010), Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials, Statistical Science, 25, 255–257.
6. B.N.Bekele,, Y.Ji,, Y.Shen,, P.F.Thall, (2008), Monitoring Late Onset Toxicities in Phase I Trials Using Predicted Risks, Biostatistics, 9, 442–457.
7. B.N.Bekele,, P.F.Thall, (2004), Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial, Journal of the American Statistical Association, 99, 26–35.
8. R.E.Bellman, (1957), Dynamic Programming, Princeton, NJ: Princeton University Press.
9. T.M.Braun,, S.Kang,, J.M.G.Taylor, (2012), A Phase I/II Trial Design When Response is Unobserved in Subjects With Dose-Limiting Toxicity, Statistical Methods in Medical Research[online].
10. T.M.Braun,, P.F.Thall,, H.Nguyen,, M.de Lima, (2007), Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent, Clinical Trials, 4, 113–124.
11. T.M.Braun,, Z.Yuan,, P.F.Thall, (2005), Determining a Maximum Tolerated Schedule of a Cytotoxic Agent, Biometrics, 61, 335–343.
12. Y.-K.Cheung, (2011), Dose Finding by the Continual Reassessment Method, London: Chapman & Hall/CRC Biostatistics Series.
13. Y.-K.Cheung,, R.Chappell, (2000), Sequential Designs for Phase I Clinical Trials With Late-Onset Toxicities, Biometrics, 56, 1177–1182.
14. S.C.Chevret, (2006), Statistical Methods for Dose Finding Experiments, Chichester, UK: Wiley.
15. S.Chib,, E.Greenberg, (1998), Analysis of Multivariate Probit Models, Biometrika, 85, 3471.
16. L.M.Collins,, S.A.Murphy,, V.N.Nair,, V.J.Strecher, (2005), A Strategy for Optimizing and Evaluating Behavioral Interventions, Annals of Behavioral Medicine, 30, 65–73.
17. M.de Lima,, R.E.Champlin,, P.F.Thall,, X.Wang,, J.D.Cook,, T.G.Martin,, G.McCormick,, M.Qazilbash,, P.Kebriaei,, D.Couriel,, E.J.Shpall,, I.Khouri,, P.Anderlini,, C.Hosing,, K.E.Chan,, P.A.Patah,, Z.Caldera,, E.Jabbour,, S.Giralt, (2008), Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine, Melphalan and Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk CD33 Positive Myeloid Leukemias And Myelodysplastic Syndrome, Leukemia, 22, 258–264.
18. M.Hernan,, B.Brumback,, J.Robins, (2000), Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men, Epidemiology, 11, 561–570.
19. P.W.Lavori,, R.Dawson, (2001), Dynamic Treatment Regimes: Practical Design Considerations, Statistics in Medicine, 20, 1487–1498.
20. Y.Li,, B.N.Bekele,, Y.Ji,, J.D.Cook, (2008), Dose-Schedule Finding in Phase I/II Clinical Trials Using a Bayesian Isotonic Transformation, Statistics In Medicine, 27, 4895–4913.
21. J.Lunceford,, M.Davidian,, A.A.Tsiatis, (2002), Estimation of the Survival Distribution of Treatment Policies in Two-Stage Randomization Designs in Clinical Trials, Biometrics, 58, 48–57.
22. E.E.M.Moodie,, T.S.Richardson,, D.A.Stephens, (2007), Demystifying Optimal Dynamic Treatment Regimes, Biometrics, 63, 447–455.
23. S.Morita,, P.F.Thall,, P.Mueller, (2010), Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics, Statistics in Biosciences, 2, 1–17.
24. S.Murphy, (2003), Optimal Dynamic Treatment Regimes (with discussion), Journal of the Royal Statistical Society, Series B, 65, 331–366.
25. ——— (2005), A Generalization Error for Q-Learning,” Journal of Machine Learning Research, 6, 1037–1097.
26. S.Murphy,, D.Bingham, (2009), Screening Experiments for Developing Dynamic Treatment Regimes, Journal of American Statistical Association, 104, 391–408.
27. S.A.Murphy,, L.M.Collins,, A.J.Rush, (2007), Customizing Treatment to the Patient: Adaptive Treatment Strategies, Drug and Alcohol Dependence, 88, S1–S3.
28. S.A.Murphy,, K.G.Lynch,, D.Oslin,, J.R.Mckay,, T.TenHave, (2007), Developing Adaptive Treatment Strategies in Substance Abuse Research, Drug and Alcohol Dependence, 88s, S24–S30.
29. S.A.Murphy,, M.J.van der Laan,, J.M.Robins, (2001), Marginal Mean Models for Dynamic Regimes, Journal of the American Statistical Association, 96, 1410–1423.
30. J.O’Quigley,, M.Pepe,, L.Fisher, (1990), Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer, Biometrics, 46, 33–48.
31. J.M.Robins, (1986), A New Approach to Causal Inference in Mortality Studies With Sustained Exposure Periods—Application to Control of the Healthy Survivor Effect, Mathematical Modeling, 7, 1393–1512.
32. ——— (1993), “Analytic Methods for Estimating HIV Treatment and Cofactor Effects,” in Methodological Issues of AIDS Mental Health Research, eds. D.G.Ostrow and R.Kessler, New York: Plenum Publishing, pp. 213–290.
33. ——— (1997), Causal Inference from Complex Longitudinal Data Latent Variable Modeling and Applications to Causality, Lecture Notes in Statistics (120), ed. M.Berkane, New York: Springer Verlag, pp. 69–117.
34. ——— (1998), Marginal Structural Models, Proceedings of the American Statistical Association Section on Bayesian Statistics, 1–10.
35. J.M.Robins,, M.A.Hernan,, B.Brumback, (2000), Marginal Structural Models and Causal Inference in Epidemiology, Epidemiology, 11, 550–560.
36. A.J.Rush,, M.Trivedi,, (2003), Depression IV: STAR*D Treatment Trial For Depression, American Journal of Psychiatry, 160, 237.
37. D.J.Spiegelhalter,, K.R.Abrams,, and J.P.Myles, (2004), Bayesian Approaches to Clinical Trials and Health-Care Evaluation, Chichester, UK: Wiley.
38. R.S.Sutton,, and A.G.Barto, (1998), Reinforcement Learning: An Introduction, Cambridge, MA: MIT Press.
39. P.F.Thall,, R.Millikan,, H.-G.Sung, (2000), Evaluating Multiple Treatment Courses in Clinical Trials, Statistics in Medicine, 19, 1011–1028.
40. P.F.Thall,, H.Q.Nguyen, (2012), Adaptive Randomization to Improve Utility-Based Dose-Finding With Bivariate Ordinal Outcomes, Journal of the Biopharmaceutical Statistics, 22, 785–801.
41. P.F.Thall,, H.Q.Nguyen,, E.H.Estey, (2008), Patient-Specific Dose-Finding Based on Bivariate Outcomes and Covariates, Biometrics, 64, 1126–1136.
42. P.F.Thall,, H.-G.Sung,, E.H.Estey, (2002), Selecting Therapeutic Strategies Based on Efficacy and Death in Multi-Course Clinical Trials, Journal of the American Statistical Association, 97, 29–39.
43. P.F.Thall,, L.H.Wooten,, C.J.Logothetis,, R.Millikan,, N.M.Tannir, (2007), Bayesian and Frequentist Two-Stage Treatment Strategies Based on Sequential Failure Times Subject to Interval Censoring, Statistics in Medicine, 26, 4687–4702.
44. M.Tokic, (2010), “Adaptive-Greedy Exploration in Reinforcement Learning Based on Value Differences, ε” in Advances in Artificial Intelligence, Heidelberg, Germany: Springer Verlag, pp. 203–210.
45. A.S.Wahed,, and A.A.Tsiatis, (2006), Semiparametric Estimation of Survival Distribution for Treatment Policies in Two-Stage Randomization Designs in Clinical Trials with Censored Data,” Biometrics, 93, 163–177.
46. ——— (2004), Optimal Estimator for the Survival Distribution and Related Quantities for Treatment Policies in Two-Stage Randomization Designs in Clinical Trials, Biometrics, 60, 124–133.
47. L.Wang,, A.Rotnitzky,, X.Lin,, R.Millikan,, P.F.Thall, (2012), Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer with discussion, Journal of American Statistical Association, 107, 493–520.
48. C.J.C.H.Watkins, (1989), “Learning From Delayed Rewards,” unpublished PhD thesis, Cambridge University.
49. G.Yin, (2012), Clinical Trial Design: Bayesian and Frequentist Adaptive Methods, New York: Wiley.
50. G.Yin,, Y.Li,, Y.Ji, (2006), Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios, Biometrics, 62, 777–789.
51. J.Zhang,, T.M.Braun, (2013), A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients, Journal of the American Statistical Association, 108, 892–901.
52. Y.Zhao,, D.Zheng,, M.A.Socinski,, M.R.Kosorok, (2011), Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer, Biometrics, 67, 1422–1433.
53. S.Zohar,, S.Chevret, (2007), Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies, Journal of Biopharmaceutical Statistics, 17, 1071–1083.